Physician
Physical Medicine/Rehab
Dr. Mark Cunningham, MD
|
|
Give Review
Mark Cunningham practices Physical Medicine/Rehab. He went to medical school at University of Tennessee College of Medicine. He over the years received 1 awards: "Top MD". Mark Cunningham is a published doctor. He published 19 publications, including: 'Down-regulation of Leishmania donovani trypanothione reductase by heterologous expression of a trans-dominant mutant homologue: effect on parasite intracellular survival.' Doctor Mark Cunningham, MD is registered with Medicare and accepts Medicare payments.
Publications
- Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided Discovery and optimization of dual targeting agents with pote...
- The role of enzymology in a structure-based drug Discovery program: bacterial DNA gyrase.
- Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani.
- Characterization of quinonoid-dihydropteridine reductase (QDPR) from the lower eukaryote Leishmania major.
- Regulation of differentiation to the infective stage of the protozoan parasite Leishmania major by tetrahydrobiopterin.
- Conservation of the LD1 region in Leishmania includes DNA implicated in LD1 amplification.
- Pteridine salvage throughout the Leishmania infectious cycle: implications for antifolate chemotherapy.
- The Leishmania donovani LD1 locus gene ORFG encodes a biopterin transporter (BT1).
- Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based Discovery of new natural product inhibitors.
- Down-regulation of Leishmania donovani trypanothione reductase by heterologous expression of a trans-dominant mutant homologue: effect on parasite intracellular survival.
- Anti-plasmodial and anti-trypanosomal activity of synthetic naphtho[2,3-b]thiopen-4,9-quinones.
- Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages.
- Overlapping expression and redundant activation of mesenchymal fibroblast growth factor (FGF) receptors by alternatively spliced FGF-8 ligands.
- The crystal structure of trypanothione reductase from the human pathogen Trypanosoma cruzi at 2.3 A resolution.
- Trypanothione reductase from Leishmania donovani. Purification, characterisation and inhibition by trivalent antimonials.
- Site-directed mutagenesis of the redox-active cysteines of Trypanosoma cruzi trypanothione reductase.
- Mechanism of inhibition of trypanothione reductase and glutathione reductase by trivalent organic arsenicals.
- Bleomycin cytotoxicity is prevented by superoxide dismutase in vitro.
Schools
University of Tennessee Memphis College of Medicine amp Surgery
Procedures Preformed
- EMG (Electromyography)
- Trigger Point Injection
Conditions Treated
- Adhesive Capsulitis
- Arthritis
- Ataxia
- Back Pain
- View All
Doctors Specialties
- Physical Medicine/Rehab
Accepted Insurances
Awards
- Top MD
Education
-
Ohio State University Hospital -
Riverside Methodist Hospitals - OhioHealth -
University of Tennessee College of Medicine
Drug Facts
| NPI NUMBER | 1326041146 | |
| NPPES Provider LastName | CUNNINGHAM | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 386714739 | |
| NPPES Provider State | MS | |
| Specialty Description | Physical Medicine and Rehabilitation | |
| Total Claim Count | 1099.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 137.0 | |
| Percent Opioid Claims | 12.47 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1326041146 |
| Last Name Of The Provider | CUNNINGHAM |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
Dr. Anne E. Brooks, DO |